English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Improvement of anti-tumor biotherapy effectiveness by modification of immuneresponse with histamine H2 receptor Cimetidinum (CM) was studied using theexperimental murine model of B16 F10 melanoma in vivo. It is shown that skinmelanoma biotherapy by antitumor whole-cell GM-CSF-producing vaccine with theaddition of CM (in dose of 25 mg/kg, daily for 5 days) increases preventiveeffects of vaccination. 33 % of mice did not have tumor growth within 60 daysof observation. Average life span of animals exceeded those of the controlgroup up to 68 %. Using CM-combined bio-chemotherapy doesn't improvetherapeutic effect, however in the case of a monotherapeutic approach tendencyfor increased average life-time and decreased metastatic processes in mice withthe developed tumors was noticed. Aquired data provides expediency to study thefurther application of CM as adjuvant for skin melanoma vaccinotherapy, andalso the necessity to verify the immune status of an organism against thecomplex bio-chemotherapy.

Prospects of using Antagonist Histamine H2-Receptor (Cimetidinum) as Adjuvant for Melanoma Biotherapy Treatment